Should I Buy IVF? IVF 2026 Analysis

Should You Buy INVO Fertility Inc (IVF) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.100

1 Day change

4.76%

52 Week Range

138.240

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: the chart is in a clear downtrend (bearish moving-average stack + weakening momentum) and there is no proprietary buy signal to justify an impatient entry.
Short-term bounce potential exists because price is sitting near key support (around $1.10), but the risk/reward is not attractive without confirmation.
Recent financing via warrant inducement is a near-term overhang (dilution/supply), which can cap upside even if the broader fertility-industry narrative is positive.

Technical Analysis

Trend: Bearish. Moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), signaling sustained downside pressure.
Momentum: MACD histogram is below zero (-0.00465) and negatively expanding, implying bearish momentum is strengthening, not stabilizing.
RSI (6): 36.36 (low/near-oversold region but still labeled neutral here) suggests sellers have been dominant; it can support a bounce, but it is not a buy trigger by itself.
Levels: Pivot at 1.526 is far above the current pre-market price (~1.06), reinforcing that price is trading below the key balance point.
- Support: S1 1.098 (immediate area), S2 0.834 (next major downside reference).
- Resistance: R1 1.954 (far overhead), indicating a lot of room before a trend reversal is confirmed.
Pattern-based odds: estimated +2.86% next day and +3.99% next week, but -2.25% over the next month—skews toward a tradable bounce risk, not a durable buy-and-hold entry.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

- Industry tailwind narrative: management expects significant fertility industry growth through 2026 (demand + tech improvements), which can support sentiment if execution improves.
- Capital raise execution: warrant inducement targets ~$7.5M gross proceeds, which could improve liquidity/runway versus prior constraints.
- Operational improvement signs: gross margin improved significantly (latest quarter) which, if sustained, can reduce cash burn over time.

Neutral/Negative Catalysts

- Dilution/overhang risk: warrant inducement includes issuance of new warrants (subject to shareholder approval), increasing potential future share supply and pressuring the stock.
- Technical weakness: bearish MA structure and worsening MACD reduce the odds of an immediate sustained reversal.
- Profitability still weak: net loss persists, and EPS deterioration suggests per-share fundamentals are not yet stabilizing (often tied to share count changes and continued losses).

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: $1.76M, up 22.60% YoY (top-line growth is positive).
Gross margin: 28.04%, up 87.56% YoY (meaningful improvement in unit economics).
Net income: -$2.64M, improved 62.18% YoY (loss narrowed).
EPS: -6.14, down 94.92% YoY (material per-share deterioration, likely impacted by capital structure/share count and ongoing losses). Overall: improving operations but weak per-share results.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target change data was provided, suggesting limited visibility from Wall Street coverage in this dataset.
Wall Street-style pros view: fertility industry growth runway + margin improvement could support a turnaround narrative.
Wall Street-style cons view: continued losses, weak per-share metrics, micro-cap liquidity/financing dependence, and dilution from warrants can keep the stock under pressure and make rallies fade.

Analyst Rating

Wall Street analysts forecast IVF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVF is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 1.050

Low

Averages

High